



Review Article

A Review on Factors Influencing the Prescribing Patterns in Paediatrics

M Bhavani, M Suresh Kumar, R Tejaswi, S Sharon, V Satyanarayana,
D R Brahma Reddy*

Nalanda Institute of Pharmaceutical Sciences, Kantepudi (V), Sattenapalli (M), Guntur (Dt), Andhra Pradesh, India.

ARTICLE INFO

A B S T R A C T

Received:19 Jul 2018
Accepted:02 Aug 2018

Paediatrics is relating to the branch of science that deals with the medical care of infants, children and adolescents. Drug utilization evaluation play a significant role in helping the health-care system to understand, explain and improve the prescribing administration and use of medications. Prescription auditing is a type of vigilance activity, which is more desirable in clinical practice in terms of reducing the burden of disease because of medication errors. Pharmacokinetics and pharmacodynamics in paediatrics differs from that of adults. Our knowledge of pharmacology of the drugs used in paediatrics has advanced with a greater understanding of their pharmacokinetics and pharmacodynamics. This has resulted in a clarification of their uses, wider indications, and alternative methods of delivery. Drug utilization evaluation studies become one of the powerful tools in evaluation of health system. Drug utilization studies focuses on factors related to prescribing, dispensing, administering and taking of medication and associated events.

Key words: Paediatrics, prescription auditing, drug utilization evaluation, pharmacokinetics, pharmacodynamics.

1. INTRODUCTION

Paediatrics is the branch of medicines dealing with the development, diseases, and disorders of children¹. Infancy and childhood is a period of rapid growth and development. Compared to adult medicine, drug use in paediatrics is not extensively researched and the range of licensed drugs inappropriate dosage form is limited. Drug therapy is considered to be a major component of paediatric management in the health care setting like hospital^{2,3}. Prescription auditing is a type of vigilance activity, which is beneficial in a clinical practice in terms of reducing the burden of disease because of medication errors. Rational use

Corresponding author *
Dr. D. R. Brahma Reddy
Professor,
Nalanda Institute of Pharmaceutical Sciences,
Kantepudi (V), Sattenapalli (M), Guntur (Dt), A.P. India-
522438
E-mail: desireddybrahma@rediffmail.com

of drugs is multifaceted. Its medical, social and economic aspects are well reflected in the WHO definition: "Rational use of drugs requires that patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements for an adequate period of time, at the lowest cost to them and their community".

Irrational prescribing is a global problem. The rationality of prescribing pattern is of utmost importance because bad prescribing habits including misuse, overuse and underuse of medicines can lead to unsafe treatment, exasperation of the disease, health hazards and economic burden on the patients and wastage of resources. Examples of irrational use of irrational use of medicines include: Polypharmacy, inadequate dosage, and use of antimicrobials even for non-bacterial infections, over use of injections when oral forms are available and inappropriate, self-medication and non-compliance to dosage regimes⁴.

Studies on proper drug utilization are necessary tools to evaluate whether drugs are appropriately utilized in terms of efficacy, safety, convenience and economic aspects at all stages in the chain of drug use⁵. Knowledge of prescribing patterns are important tools for a rational drug therapy. For all drug users rational drug therapy is important, but it is of utmost importance for paediatrics⁶. Several drugs were frequently used for children; though they were having been investigated in adult's only. Nevertheless pharmacokinetics as well as pharmacodynamics in paediatrics differs from that of adults⁷⁻⁹. Children are among the most sensitive groups to possible harmful effects of drugs as they are physiologically different from adults. It is therefore important to establish which drugs can be used for children and to discover those which are not harmful. So, rational prescribing pattern and providing correct information during dispensing is good for proper utilization of drugs¹⁰.

Over 60% of children in hospitals and 90% of those in intensive care units receives unlicensed or off-label drug. Example of such drug is captopril, levofloxacin, gabapentin, dexmedetomidine e and morphine. Often, information about the dose in milligrams per kilograms of body weight for their drugs is not available and the practitioner is left to estimate a children dose based on the adult dose, using certain formulae give below¹¹.

Clark's Rule:

$$\frac{(\text{Weight in pounds}) \times (\text{Adult dose})}{150}$$

Fried's Rule:

$$\frac{(\text{Age in months}) \times (\text{Adult dose})}{150}$$

Young's Rule:

$$\frac{(\text{Age in years}) \times (\text{Adult dose})}{\text{Age}+12}$$

Prescribing indication measurements¹²

The WHO prescribing indication was pretested and slight modification was made to make it application in Indian scenario before using in this study. The formula adopted

from WHO manual for the assessment prescribing indicators used in this study are as follows:

1. Average number of drugs par encounter= Total number of drugs prescribing/ Total number of encounters sample. Combinations of drugs prescribing for one health problem were counted as one.
2. Percentage of drugs per encounter = (Number of drugs prescribed by generic name/ Total number of drugs prescribed) × 100.
3. Percentage of encounters with an antibiotic prescribed = (Number of patient encounters with an antibiotic/ Total number of encounter sample) × 100
4. Percentage of encounters with an injection prescribed = (Number of patients encounters with an injection prescribed/ Total number of encounters sample) × 100
5. Percentage of drugs prescribed from essential drugs list = (Number of drugs prescribed from essential drugs list / Total number of prescribed drugs) × 100.

PHARMACODYNAMIC CONSIDERATIONS

Pharmacodynamic Covariates

Considerable strides have been made recognizing Pharmacodynamic covariates. Bradycardia during anaesthetic persuade with sevoflurane was common in children with Down syndrome¹³. Severe illness is a major explicit for the clearance midazolam¹⁴. Opioid administration was decreased in healthy children with altitude induced chronic hypoxia when compared with non hypoxic children undergoing identical operations under similar anaesthetic regimens¹⁵. Opioid dose also appears to different geographically; that is, children in central and South America receive less opioid intra operatively than children in Africa and India, under standardized anesthesia for cleft surgeries. Culture may contribute to this observation. There were differences in the episodes of adverse effects after morphine administration between Latino and non Latino Caucasian children. Incomplete differences in morphine or polymorphisms examined, explained these findings¹⁶.

The management of postoperative pain can only improve with greater understanding of its severity and duration. Children experience notable pain and severe functional limitation up to 7days after tonsillectomy or orchidopexy; effects that may persist into the second postoperative week¹⁷. Substantial pain continue on day 2 even after laparoscopic appendectomy¹⁸. With intellectual disability (e.g., Trisomy 22) suffer post-operative pain to a identifiable effects as unaffected children, leading many to advocate similar preoperative analgesia care for the two groups^{19,20}.

"Jet Lag" After Anesthesia

Children often experience sleep disturbance after anesthesia. Part of this effect may be assign to disruption of the internal circadian clock. The honey bee has a circadian clock that is alike to that found in humans. After a 6hr anaesthetic, bees showed a delay in the start of hunt and whole-hive locomotor- activity rhythms that were slowed by an average

of 4.3 h. Messenger RNA of circadian clock genes was altered by anesthetic exposure, recommend that general anesthesia changes the circadian clock in a manner consistent with jet lag²¹.

2. PHARMACOKINETICS²²

Pharmacokinetics deals with the processes of drug absorption, distribution, metabolism, and elimination.

Absorption

Absorption from the GI tract is simulated by

- Gastric acid secretion
- Bile salt formation
- Gastric emptying time
- Intestinal motility
- Bowel length and effective absorption surface
- Microbial flora

All these factors turn down in neonates (full-term and premature) and all may be reduced or increased in an ill child. Reduced gastric acid secretion increased bioavailability of acid-labile drugs and decreases bioavailability of weakly acidic drugs. Reduced bile salt formation decreases bioavailability of lipophilic drugs.

Reduced gastric emptying and intestinal motility increase the time it takes to reach therapeutic concentrations when enteral drugs are given to infants below 3 months. Drug-metabolizing enzymes present in the intestines of infants are another cause of reduced drug absorption.

Injection

Injected drugs are often absorbed due to

- Divergence in their chemical characteristics
- Differences in absorption by the site of injection (IM or SC)
- Variability in muscle mass among paediatrics
- Illness among paediatrics
- Difference in depth of injection (too deep or too shallow)

Transdermal

Transdermal absorption may be increased in neonates and young infants because their stratum corneum is thin and because the ratio of surface area to weight is very much greater than for children and adults.

Transrectal

Transrectal drugs therapy is generally appropriate only for emergencies when an IV route is not available (e.g., use of rectal diazepam for status epilepticus). Site of administration of drug within the rectal cavity may influence absorption because of the variation in venous drainage systems.

Inhalation

Absorption of inhaled drugs from the lungs (e.g., beta-agonist for asthma) varies less by physiologic factors and by reliability of the delivery and patient or caregiver technique.

Distribution

The volume of distribution of drugs changes in children with aging process. These age-related changes are due to changes

in body composition (especially the extracellular and total body water spaces) and plasma protein binding.

Higher doses (per kg of body weight) of water-soluble drugs are required by younger children because a higher percentage of their body weight. Conversely, lower doses are required to avoid toxicity as children grow older because of the decline in water as a percentage of body weight.

Metabolism and elimination

Drugs metabolism and elimination differs with age and depend on the substrate or drug, but most drugs, and most notably phenytoin, barbiturates, and cardiac glycosides, have plasma half-life 2 to 3 times greater in neonates than in adults.

The cytochrome P-450(CYP 450) enzyme in the small bowel and liver is the most important known system for drug metabolism. CYP450 enzymes inactivate drugs via

- Oxidation, reduction, and hydrolysis (phase I metabolism)
- Hydroxylation and conjugation(phase II metabolism)

Phase I metabolism activity is decreased in neonates, increases progressively during the first 6 months of life, exceeds adult rates by the first few years for some drugs, slows during adolescence, and usually attains adult rates by late puberty. However, adult rates of metabolism may be achieved for some drugs (e.g., phenytoin) 2 to 4 weeks postnatal.

Phase II metabolism varies mainly by substrate. Maturation of enzymes responsible for bilirubin and acetaminophen conjugation is slowed.

Drug metabolites are eliminated primarily through bile or the kidneys. Renal elimination depends mainly on

- Plasma protein binding
- Renal blood flow
- GFR
- Tubular secretion

All of these factors are altered in the first 2 years of life. Renal plasma flow is low at birth (12ml/min) and reaches adult levels of 140 ml/min by age 1 year. Similarly, GFR is 2- 4 ml/min at birth, increases 8 to 20 ml/min by 2 to 3 days, and reaches adult levels of 120ml/min by 3-5 months

Drug dosing

Because of the above factors, drug dosing in children less than 12 yrs is always a function of age, body weight, or both. This approach is practical but not ideal. Even within a population of approximately same age and weight, drug requirements may differ because of maturational differences in absorption, metabolism, and elimination. Thus, when practical, dose adjustments should be depending on plasma drug concentration (however, plasma drug concentration may not reflect the drug concentration in the target organ).

3. DRUG UTILIZATION EVALUATION

Rational drug use is an important factor to be checked for the optimal benefit of drug therapy in patient care²³. In India,

many factors like illiteracy poverty, use of multiple health care system, drug advertising and promotion, sale of prescription, competition in medical and pharmaceutical market place and limited availability of drug information are the main reasons for not achieving the optimal health care²⁴. Inappropriate use of drug also leads to increased cost of medical care, antimicrobial resistance, adverse effects and utilization evaluation (DUE) studies becomes one of the potential tools in evaluation of health system^{23, 25}. Drug utilization studies focuses on factors related to prescribing, dispensing, administering and taking of medication and associated events²³.

Classification of Drug Utilization Evaluation

DUR is typically classified into three different categories,

1. Prospective DUR:

Prospective review evaluation a patients planned drug therapy before a medication described. This DUR helps the pharmacist to access the prescription medications and resolve drug related problems^{23, 25, 26}.

2. Concurrent DUR:

It is performed during the course of treatment and the ongoing monitoring of drug therapy for the positive patient outcomes^{23, 26}.

3. Retrospective DUR:

It is a review of drug therapy after the patient has received the medication. A retrospective review aims to detect the pattern in prescribing, dispensing or advertising drugs and it helps to prevent recurrence of inappropriate medication use. The advantage of this DUR is ease of data collection, as records are assessed at the data collector's convenience. A disadvantage is that some information may be unclear or missing and reviewed patients may not gain immediate benefit, as interventions are delayed until the intervention phase^{23, 25, 26}.

Steps in DUE^{23, 25}

Drug utilization evaluation process is divided into four phases

PHASE 1: PLANNING

1. Develop a DUR committee.
2. Write policies and procedures.
3. Describe about the departments of the hospital, where drugs are utilized (intensive care unit, radiology, surgical department, medical department).
4. Select specific drugs for possible inclusion in the program.
5. Assess resources available for critical development, data collection, and evaluation.
6. Consider the indications, dosing, dosage form, frequency of drug used to monitor and evaluate.
7. Select criteria and establish performance thresholds.
8. Develop the methodology for data collection, evaluation and create a schedule.
9. Educate hospital staff about DUE study and current criteria.

PHASE 2: DATA COLLECTION AND EVALUATION

1. Start the data collection in proper way.
2. Evaluate the collected data and determine if drug use problem exist.

PHASE 3: INTERVENTIONS

1. Send the results to hospital staff.
2. If a drug use problem was found, design and implement interventions.
3. Collect new data on problem drug to determine with drug use has improved as a result of the intervention.
4. Disseminate results of re-evaluation.

PHASE 4: PROGRAM EVALUATION

1. Evaluate all DUR program activities at the end of the year, and plan the new activities for the upcoming year.

4. CONCLUSION

Prescription auditing gives a clear picture of the prescribing practices in our hospital setting. The WHO core indicators helped to improvise the prescribing pattern, identify significant problems involved in the knowledge gap of patients or caretakers understanding of instructions provided by consultants and even to minimize the cost burden on patient. With the help of pharmacokinetic of a drug, interactions between drugs, and the Pharmacodynamic effects of these findings in different subpopulations of infants and children, we can identify the key covariates that will enable clinicians to prescribe effective doses of drugs while limiting the adverse effects in the individual child.

5. REFERENCES

1. Ghai OP. Essential Paediatrics. Fourth edition. New Delhi, India: Interprint; 2002.
2. Sanz EJ, Bergman U, M. Dahl storm. Paediatric drug prescribing. Eur J Clin Pharmacol 1989; 37:65-68.
3. Summers RS, B. Summers. Drug prescribing in Paediatrics. Ann Trop paediatr 1986;6:129-133.
4. Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J Clin Pharmacol 1995;39:1-6.
5. MNG Dukes (ed.). Drug utilization studies: methods and use. WHO Region Publications. Eur Ser No 45. Who regional Officer for Europe, WHO, Copenhagen, 1993.
6. Sanz EJ. Drug use in non-hospitalized children. Pharm Weekbl Sci 1992; 14(1):1-8.
7. Impicciatore P, I. Choonara. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999;48(1):15-18
8. Wilton LV, Pearce G, RD. Mann. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 1999;8(suppl 1): S37-45.
9. Conroy S, Choonara I, Impicciatore P, Mohn A, H. Arnell, A. Rane. Survey of unlicensed and off label drug

- use in paediatric wards in European countries. European Net works for Drug Investigation in children. Br Med J 2000; 320(7227);79-82.
10. Drug Administration and Control Authority of Ethiopia. Introduction Standard Treatment Guidelines for Zonal hospitals. First edition. Addis Ababa, Ethiopia: Chamber printing House, 2004.
 11. Parthasarathi G, Karin Nyfort-Hanse, Milap C Nahata. A Textbook of Clinical Pharmacy Practice. Second edition 2012.
 12. Anandhasayanam A, Mohanavalli A, Kannan Subramaniam and Sam Johnson J Udaya Chander. Assessment of current prescribing practices using World Health Organization core drug use and complementary indicators in selected rural community pharmacies in Southern Indian. Journal of pharmaceutical Policy and Practice (2017) 10:11:3.
 13. Kraemer FW, Stricker PA, HG. Gurnaney. Bradycardia during induction of anesthesia with sevoflurane in children with Down syndrome. Anesth Analg. 2010;111(5):1259-1263.
 14. Ince I, SN. de Wildt, MY. Peeters. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit. 2012;34(4):381-389.
 15. Rabbitts JA, Groenewald CB, J. Rorales. Perioperative opioide requirement are decreased in hypoxic children living at altitude. Pediatr Anesth. 2010;20(12): 1078-1083.
 16. Jimenez N, Anderson GD, DD. Shen. Is ethnicity associated with morphine's side effects in children? Morphine dren having tonsillectomy. Pediatr Anesth. 2012;22(7):669-675.
 17. Steward DW, Ragg S PG Sheppard, GA. Chalkiadis. The severity and duration of postoperative pain and analgesia inguinal hernia repair. Pediatr Anesth. 2012;22(2):136-143.
 18. Tomecka MJ, Bortsov AV, R. Miller. Substantial post-operative pain is common among children undergoing laparoscopic appendectomy. Pediatr Anesth. 2012;22(2): 130-135.
 19. Makkar JK, Singh NP. Absence of perioperative analgesia in children with cerebral palsy: how justified is it? Pediatric Anesthesia. 2012;22(2):178.
 20. Walker SM. Perioperative care of neonates with Down's syndrome: should it be different? Br J Anaesth. 2012; 108(2):77-79.
 21. Cheeseman JF, EC. Winnebeck, CD. MILLar. General anesthesia alters time perception by phase shifting the circadian clock. Proc Natl Acad Sci USA. 2012;109(18):7061-7066.
 22. Bridgette L. Jones. Pharmacokinetics in Children. Merck Sharp & Dohme Corp. A subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA 2018.
 23. Sachdeva PD. Drug utilization studies- Scope and future perspectives. Ijpb 2010; 1(1): 11-17.
 24. Shalini S, Ravichandran V, BK. Mohanty, SK. Dhanraj, R. Saraswathy. Drug utilization studies- an overview. Int. J. Pharm. Sci. Nanotech 2010; 3(1):803-810.
 25. Thomas M, Alexander B, Tony S, Andre Zi. Guidelines for implementing drug utilization review programs in hospitals. Russia: Management Sciences for Health: 1997.
 26. Robert N. Managed Care Pharmacy Practice. Second edition. USA: Jones and Barlett Learning; 2008.

Conflict of Interest: None

Source of Funding: Nil